Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Sex: All

Ages: 18 Years – N/A

Phase: PHASE2, PHASE3

Enrollment: 120

Sponsor: Western Institute for Veterans Research

Summary

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

Eligibility Criteria

Inclusion Criteria:Must be able to understand and provide written informed consentAge 18 or olderClinical diagnosis of cutaneous wartsMust have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)Exclusion Criteria:Untreated cutaneous wartsAnogenital wartsOral wartsTreatment for cutaneous warts in the past 4 weeksActive acute illnessImmunosuppressionKnown hypersensitivity to HPV vaccinationSubjects may not receive any other investigational treatmentPregnancy or planned pregnancy during the study period

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05625633). StuddyBuddy aggregates publicly available trial information.